<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A higher complete remission (CR) rate was observed in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) who, on a prior randomized study of induction therapy, received gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) plus interleukin-11 (IL-11) rather than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> alone </plain></SENT>
<SENT sid="1" pm="."><plain>An adaptive randomized phase III study of the addition of IL-11 to <z:chebi fb="0" ids="42068">idarubicin</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (IA) induction in 100 patients &gt;/=50 years of age with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was conducted </plain></SENT>
<SENT sid="2" pm="."><plain>Median patient age was 67 years (range 50-82) </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-four of the 45 (53%) patients randomized to IA plus IL-11 achieved CR </plain></SENT>
<SENT sid="4" pm="."><plain>Eight (33%) subsequently relapsed, 4 (17%) died in CR; median time to treatment failure (<z:chebi fb="6" ids="52444">TTF</z:chebi>) was 37 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-nine of the 55 (53%) patients treated without IL-11 achieved CR </plain></SENT>
<SENT sid="6" pm="."><plain>Eight (28%) subsequently relapsed, 2 (7%) died in CR; median <z:chebi fb="6" ids="52444">TTF</z:chebi> was 46 weeks </plain></SENT>
<SENT sid="7" pm="."><plain>Median overall survivals were 21 and 59 weeks for the IA plus IL-11 and IA cohorts, respectively (p=0.271, log rank test; 0.435, Gehan-Breslow test) </plain></SENT>
<SENT sid="8" pm="."><plain>Ten episodes of the following grade 3 or 4 cardiopulmonary toxicities were observed in patients receiving IA plus IL-11, 12 such episodes in those receiving IA alone: <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, <z:hpo ids='HP_0002202'>pleural effusions</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001662'>bradycardia</z:hpo> or <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients in each arm experienced grade 3 peripheral <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>There was no significant difference in incidence of any grade 3 or 4 adverse event, including <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, between treatment arms </plain></SENT>
<SENT sid="11" pm="."><plain>There was no significant impact on CR rates, <z:chebi fb="6" ids="52444">TTF</z:chebi>, survival, or toxicity of adding an IL-11 regimen to IA induction in patients &gt;/=50 years of age with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>